Antimicrobial activities of ozenoxacin against isolates of propionibacteria and staphylococci from Japanese patients with acne vulgaris

Abstract

Ozenoxacin, a novel non-fluorinated topical quinolone, was assessed for in vitro antimicrobial activity against clinical isolates of propionibacteria and staphylococci according to the broth microdilution method recommended by the Clinical and Laboratory Standards Institute. The isolates used in this study were collected from Japanese patients with acne vulgaris during a period from 2012 to 2013. The MIC 90 s of ozenoxacin against Propionibacterium acnes (n=266), Propionibacterium granulosum (n=10), Staphylococcus aureus (n=23), Staphylococcus epidermidis (n=229) and other coagulase-negative staphylococci (n=82) were 0.06, 0.06, 0.06, 0.125 and 0.06 µg ml À1 , respectively. The antimicrobial activity of ozenoxacin against the clinical isolates of propionibacteria and staphylococci was greater than that of five reference antimicrobial agents which have been used for the treatment of acne vulgaris. The MICs of ozenoxacin were correlated with those of nadifloxacin in P. acnes and S. epidermidis isolates. However, the MICs of ozenoxacin were 0.25-0.5 µg ml À1 and 0.5-8 µg ml À1 against nadifloxacin-resistant P. acnes (MIC: !8 µg ml À1 ; n=8) and S. epidermidis (MIC: !64 µg ml À1 ; n=10), respectively. These results indicated the potent antimicrobial activity against P. acnes and S. epidermidis isolates resistant to nadifloxacin. Topical ozenoxacin could represent an alternative therapeutic drug for acne vulgaris based on its potent antimicrobial activity against the isolates of propionibacteria and staphylococci from acne patients.

Comparative in Vitro Antibacterial Activity of Ozenoxacin Against Gram-Positive Clinical Isolates

“…25 mg/l in study 1 and study 2, respectively, against S. epidermidis; and 0.12 mg/l in both studies 1 and 2 against coagulase-negative staphylococci. The MIC 90 of ozenoxacin against Propionibacterium acnes was ≤0.06 mg/l in the Japanese study [18], but strains of this species were not included in the present study.…”

“…A second Japanese study of the antimicrobial activity of ozenoxacin against isolates from patients with acne vulgaris reported MIC 90 values of ozenoxacin against S. aureus, S. epidermidis and other coagulase-negative staphylococci of ≤0.06, 0.125 and ≤0.06 mg/l, respectively [18]. In comparison, in the present studies, ozenoxacin MIC 90 values were 0.25 and 0.06 mg/l in study 1 and study 2, respectively, against S. aureus; 1 and 0.…”

Relationship between quinolone use and resistance of Staphylococcus epidermidis in patients with acne vulgaris

“…Ozenoxacin, which is a new topical antimicrobial agent for the treatment of skin infections, was approved for clinical use in 2015 in Japan. Because little is known about the potency of ozenoxacin, we evaluated the efficacy of ozenoxacin against high‐level levofloxacin‐resistant strains. We found that ozenoxacin exhibited higher potency than the other quinolones against the strains with two substitutions in both GyrA and ParC.…”

Therapeutic Efficacy of Ozenoxacin in Animal Models of Dermal Infection with Staphylococcus Aureus

“…Ozenoxacin produced a superior clinical and microbiological response when compared with placebo [13,14], and had similar efficacy to retapamulin but showed more rapid microbiological clearance than retapamulin [13]. In Japan, ozenoxacin is used for the treatment of acne vulgaris [20,21].…”